Evaluating Relmacabtagene Autoleucel for Large B-cell Lymphoma
A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma
This study is testing if a new treatment called Relmacabtagene autoleucel can help adults with large B-cell lymphoma that has come back or hasn’t responded to other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Ming Ju Biotechnology Co., Ltd. Industry-sponsored |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT06142175 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the efficacy and safety of Relmacabtagene autoleucel in adult patients with relapsed or refractory large B-cell lymphoma. It will collect real-world data over a six-month period following treatment, utilizing both prospective and retrospective approaches. Physicians will determine the appropriate diagnostic and therapeutic regimens based on standard clinical practices, without any therapeutic intervention being mandated by the study. The study will analyze data collected to evaluate outcomes in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients with established relapsed or refractory large B-cell lymphoma who have already received treatment with Relmacabtagene autoleucel.
Not a fit: Patients who have not been treated with Relmacabtagene autoleucel or those with other types of lymphoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness and safety of Relmacabtagene autoleucel for patients with large B-cell lymphoma.
How similar studies have performed: Other studies evaluating CAR T-cell therapies have shown promising results, indicating that this approach has potential based on previous successes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients with established r/r LBCL; 2. Patients already treated with commercially available Relmacabtagene Autoleucel Exclusion Criteria: No
Where this trial is running
Shanghai, Shanghai
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Weili Zhao, PhD — Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
- Study coordinator: Medical JWCAR029, PhD
- Email: JWCAR029Medical@jwtherapeutics.com
- Phone: +86 21 50464201
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.